CBV (chemotherapy)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

CBV refers to Cytoxan (cyclophosphamide), BCNU (carmustine), and VP-16 (etoposide), three drugs in a chemotherapy regimen commonly given to lymphoma patients in conjunction with stem cell therapy.[1]

CBV is usually given in high doses to patients who have relapsed or who have refractory disease and cannot benefit from standard chemotherapy. Since a patient's bone marrow is virtually guaranteed not to survive a course of CBV, the receiving patient must receive a transplant (allogeneic or autologous, depending on his or her condition) of stem cells (formerly referred to as a bone marrow transplant) to replace the patient's own hemopoietic ("blood-forming") stem cells.[2]

See also[edit]


  1. ^ Skeel, Roland T. Handbook of Cancer Chemotherapy, 6th Edition. Philadelphia: Lippincott Williams & Wilkins, 2003. Page 172-3, Table 5.4: "Common preparative regimens for high-dose therapy without total-body irradiation."
  2. ^ "Alternatives to Blood Transfusions for Patients." Penn Online Today. Jan./Feb. 2004. <http://www.pennhealth.com/phys_forum/pto/jan_feb04/blood.html">